Fogorvosi szemle, 1993 (86. évfolyam, 1-11. szám)
1993-04-01 / 4. szám
hormone or calcitonin in intact rats. Metab. Bone Dis. Relat. Res. 2, 339. 1981. — 7. Baron, R. és mis.: The significance of lacunar erosion without osteoclasts: studies on the reversal phase of the remodeling sequence. In: Bone Histomorphometry, W. S. S. Jee ,,A. M. Parfitt, eds. 1980. — 8. Baylink, D. J. & Liu, C. C.: The regulation of endosteal bone volume. J. Periodontol. 50. Special Issue 43. 1979. — 9. Binderman, I. és mts.: The transduction of mechanical forces into biomechanical events in bone cells may involve activation of phospholipase A2. Calcif. Tissue Int. 42: 261. 1988. — 10. Blumenkrantz, N. & Sondergraad, JEffect of prostaglandin E, and Fta on biosynthesis of collagen. Nature (New Biol) 239, 246. 1972. — II. Blunt, J. W. és mts.: 25-hydroxycholecalciferol. A biologically active metabolite of vitamin D3. Biochemistry 7, 3317. 1968. — 12. Burows, R.: Variations produced in bones of growing rats by parathyroid extracts. Am. J. Anat. 62, 237. 1938. — 13. Canalis E. M. <fc Raisz, L. G.: Effect of sex steroids on bone collagen synthesis in vitro. Calcif. Tissue Res. 25, 105. 1978. — 14. Cantly, L. K. és mts.: Effects of vitamin D3, 25-hydroxyvitamin 1):! and 24,25-dihydroxyvitamin D3 on parathyroid hormone secretion. Calcif. Tissue Int. 41, 48. 1978. — 15. Chambers, T. J.: The cellular basis of bone resorption. Clinical Orthop. Rel. Res. 151, 283. 1980. — 16. Chambers, T. J. Magnus, C. J.: Calcitonin alters behaviour of isolated osteoclasts. J. Pathol. 136, 27. 1982. 17. Chambers, T. J. dk Dunn, C. J.: Pharmacological control of osteoclastic motility. Calcif. Tissue Int. 35, 566. 1983. — 18. Chambers, T. J. & Ali, N. N.: Inhibition of osteoclastic motility by prostaglandins I2, E,, E2 and 6-oxo-E,. J. Pathol. 139, 383. 1983. — 19. Chambers, T. .7. <0 Fuller. K.: Bone cells predispose bone surfaces to resorption by exposure of mineral to osteoclastic contact. J. Cell. Sei. 76, 155. 1985. — 20. Chyun, Y. S. & Raisz, L. G.: Stimulation of bone formation by prostaglandin E2. Prostaglandins 27, 97. 1984. — 21. Davidovitch, Z. <fc Shanfeld, J. L.: Prostaglandin E2 (PGE2) levels in alveolar bone of orthodontically treated cats. J. Dent. Res. 59B, 977. 1980. — 22. Dekel, 8. és mts.: Release of prostaglandins from bone and muscle after tibial fracture: An experimental study in rabbits. J. Bone & Joint Surgery 633, B, 185. 1985. — 23. DeLuca, H. F.: The kidney as an endocrine organ involved in the function of vitamin D. Amer. J. Medicine 58, 40. 1975. — 24. DeLuca, H. F. <L Schnoes, H. K.: Metabolism and mechanism of action of vitamin D. Annu. Rev. Biochem. 45, 631. 1977. — 25. Dietrich, J. W. és mts.: Hormonal control of bone collagen synthesis in vitro: effects of parathyroid hormone and calcitonin. Endocrinology 98, 943. 1976. — 26. Dominguez, J. H. <fc Mundy, G. R.: Monocytes mediate osteoclastic bone resorption by prostaglandin production. Calcif. Tissue Int. 31, 29. 1980. — 27. Elattar, T. M. A. <fc Lin, H. S.: Prostaglandin in gingiva of patients with periodontal disease. J. Periodontol. 52, 16. 1971. — 28. Eugenidis, N. és mts.: Osteosclerosis in hyperparathyroidism. Radiology 105, 265. 1972. —29. Feyen, J. H. M. és mts.: Stimulation of arachidonie acid metabolism in primary cultures of osteoblast — like cells by hormones and drugs. Prostaglandins 28, 769. 1984. — 30. Fraser, D. R. <fc Kodicek, E. : Unique biosynthesis by kidney of a biologically active vitamin D metabolite. Nature (London) 228, 764. 1970. — 31. Fredmann, J. & Raisz, L. G.: Thyrocalcitonin: Inhibitor of bone resorption in tissue culture. Science 150, 1465. 1965. — 32. Frost, H. M: A method of analysis of trabecular bone dynamics. In: Bone Histomorphometry. PJ. Meunier. ed. Lab. Armour Montagu, Paris pp: 445—476. 1977. — 33. Gera, I. és mts.: Indomethacin does not inhibit the anabolic effect of parathyroid hormone in rats. J. Bone and Mineral Res. 1. Suppl. 133. 1986. — 34. Gera, I. és mts.: Indomethacin does not inhibit the anabolic effect of parathyroid hormone on the long bones of rats. Calcif Tissue Int. 40, 206. 1986. — 35. Gera, 1. és mts.: Human parathyroid hormone 1—34 increases bone mass in ovariectomized and orchidectomized rats. J. Bone and Mineral Res. 2, Suppl. 55. 1987. — 36. Giallard, P. ,1. és mts.: Effects of parathyroid hormone and synthetic fragment (PTH 1 34) on bone in vitro. Proc. K. Ned. Acad. Vet. (Biol. Med.) C80, 267. 1977. —37. Goodson, J. M.: Prostaglandins: Potential mediators of periodontal disease. J. Dent. Res. IADR abstr. 375. 1972. — 38. Goodson, J. M. és mts.: Prostaglandin E2 levels and human periodontal disease. Prostaglandins 6, 81. 1974. — 39. Goodson, J. M. és mts.: Prostaglandin induced resorption of the rat calvarium. J. Dent. Res. 53, 670. 1974. — 40. Gunness-Hey, M. és mts.: Human parathyroid hormone (1—34) and salmon calcitonin do not reverse impaired mineralization produced by high doses of 1,25 dihydroxyvitamin D3. Calcif. Tissue Int. (1986) 38, 234. 1986. — 4L Gunness-Hey, M. és mts.: Effect of low dose 1,25 (OH)2D3 on bone growth. J. Bone and 116
